NovaBridge Biosciences
0VY
Company Profile
Business description
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
30
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,845.60 | 51.40 | -0.58% |
| CAC 40 | 8,077.80 | 3.63 | -0.04% |
| DAX 40 | 25,408.64 | 142.11 | 0.56% |
| Dow JONES (US) | 51,828.62 | 478.64 | 0.93% |
| FTSE 100 | 10,695.25 | 15.26 | 0.14% |
| HKSE | 24,510.09 | 251.04 | -1.01% |
| NASDAQ | 27,068.72 | 129.34 | 0.48% |
| Nikkei 225 | 66,364.20 | 850.21 | 1.30% |
| NZX 50 Index | 13,811.11 | 13.72 | -0.10% |
| S&P 500 | 7,743.41 | 39.28 | 0.51% |
| S&P/ASX 200 | 8,665.00 | 37.00 | -0.43% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |